Tech Company Financing Transactions
Fractyl Laboratories Funding Round
Private investors participated in a $19.8 million funding round for Fractyl Laboratories. The round was announced by the company on 9/4/2014.
Transaction Overview
Company Name
Announced On
9/4/2014
Transaction Type
Venture Equity
Amount
$19,764,908
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
17 Hartwell Ave.
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Undisclosed
Website
Email Address
Overview
Fractyl is developing Revita DMR, a same-day, minimally invasive procedure to treat two highly prevalent metabolic diseases: type 2 diabetes and NAFLD/NASH. The Revita DMR procedure harnesses breakthrough insights in the role of the duodenum in causing insulin resistance and metabolic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Harith Rajagopalan
Chief Financial Officer
Lisa Davidson
Chief Medical Officer
Juan Lopez-Talavera
President
Jay Caplan
Vice President
Kelly White
VP - Bus. Development
Margaret Borys
VP - Manufacturing
Len Rosberg
VP - Regulatory Affairs
Jon Fitzgerald
Browse more venture capital transactions:
Prev: 9/4/2014: IEX venture capital transaction
Next: 9/4/2014: SHINE Medical Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs